Jefferies Group LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Jefferies Group LLC

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2022 Sep 21, 2023	SELL	$234.96 - $292.55 $19.9 Million - $24.8 Million	-84,800 Reduced 99.76%	200 $56,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $19.9 Million - $24.8 Million	-84,800 Reduced 99.76%	200 $56,000
Q3 2021 Sep 21, 2023	BUY	$181.39 - $202.99 $10.9 Million - $12.2 Million	60,000 Added 240.0%	85,000 $15.4 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $10.9 Million - $12.2 Million	60,000 Added 240.0%	85,000 $15.4 Million
Q2 2021 Aug 20, 2021	SELL	$187.49 - $221.1 $464 Million - $547 Million	-2,475,000 Reduced 99.0%	25,000 $5.04 Million

Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $464 Million - $547 Million	2,475,000 Added 9900.0%	2,500,000 $5.04 Million
Q1 2021 Sep 21, 2023	BUY	$207.02 - $241.31 $5.13 Million - $5.98 Million	24,800 Added 12400.0%	25,000 $5.37 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $2.75 Million - $3.21 Million	13,300 Added 113.68%	25,000 $5.37 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $4.04 Million - $5.01 Million	-20,200 Reduced 63.32%	11,700 $2.78 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $3.67 Million - $4.93 Million	-22,000 Reduced 40.82%	31,900 $6.99 Million
Q3 2019 Nov 13, 2019	SELL	$166.23 - $187.09 $4.45 Million - $5.01 Million	-26,800 Reduced 33.21%	53,900 $9.13 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $9.01 Million - $11.4 Million	-59,300 Reduced 42.36%	80,700 $13.4 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $20.4 Million - $23.8 Million	140,000 New	140,000 $23.8 Million

1,623

222M

1.35M

1.49M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.